18
Dec
2015

Shkreli Gets Pinched, Cruz Tries to Kneecap FDA & Woodford’s Nutty Investment

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

BMS Hits IPF Goal, Iambic Goes Public & AZ Invests in Insitro
Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO
Enveda Cashes In, Otsuka Hits ALS Goal, & Viking Braces for GLP-1 Battle
Scholar Rock Gets FDA OK, Reverse Mergers Continue & Novartis Bets on Brain Delivery